Modality
Nanobody
MOA
GLP-1ag
Target
C5
Pathway
DDR
UCPsoriasisAML
Development Pipeline
Preclinical
~Nov 2012
→ ~Feb 2014
Phase 1
~May 2014
→ ~Aug 2015
Phase 2
~Nov 2015
→ ~Feb 2017
Phase 3
May 2017
→ Jul 2031
Phase 3Current
NCT06984936
1,649 pts·Psoriasis
2024-06→2031-06·Active
NCT03030928
2,794 pts·Psoriasis
2022-08→2031-07·Active
NCT08512579
436 pts·Psoriasis
2024-02→2030-07·Active
+1 more trial
5,690 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2030-07-274.3y awayPh3 Readout· Psoriasis
2030-08-284.4y awayPh3 Readout· AML
2031-06-035.2y awayPh3 Readout· Psoriasis
2031-07-075.3y awayPh3 Readout· Psoriasis
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Recruit…
P3
Active
P3
Active
P3
Active
Catalysts
Ph3 Readout
2030-07-27 · 4.3y away
Psoriasis
Ph3 Readout
2030-08-28 · 4.4y away
AML
Ph3 Readout
2031-06-03 · 5.2y away
Psoriasis
Ph3 Readout
2031-07-07 · 5.3y away
Psoriasis
RecruitingActive|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06984936 | Phase 3 | Psoriasis | Active | 1649 | EDSS |
| NCT03030928 | Phase 3 | Psoriasis | Active | 2794 | OS |
| NCT08512579 | Phase 3 | Psoriasis | Active | 436 | PANSS |
| NCT04561391 | Phase 3 | AML | Recruiting | 811 | MRD |
Competitors (10)